Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Prototype Test Developed for Ocular Trachoma

By LabMedica International staff writers
Posted on 15 Aug 2011
An evaluation has been made of a prototype point-of-care (POC) test, developed for field diagnosis of ocular Chlamydia trachomatis, in low prevalence settings. More...


The clinical signs of active trachoma are often present in the absence of ocular C. trachomatis infection in low prevalence and mass treated settings and treatment decisions are currently based on the prevalence of clinical signs.

A simple point-of-care (POC) test has been compared in laboratory testing for C. trachomatis infection to a polymerase chain reaction (PCR) which is highly sensitive but expensive and requires well-trained staff. Scientists from the London School of Hygiene and Tropical Medicine, (London, UK), working with others in the Gambia and Sengal screened children under the age of 10 for signs of trachoma. Two ocular swabs were taken from the right eye. The first swab was tested by the POC test in the field. This assay detects the chlamydial lipopolysaccharide (LPS), using lateral flow technology and this assay was designed specifically for use in resource-limited settings, and therefore has no electricity, water, or laboratory equipment requirements. The second swab was tested for the presence of C. trachomatis by Amplicor PCR.

A total of 3,734 children were screened, 950 in the first and 1,171 in the second Gambian study, and 1,613 in Senegal. The sensitivity of the prototype POC test (Diagnostics Development Unit, University of Cambridge, UK), ranged between 33.3% and 67.9%, the specificity was between 92.4% and 99.0%. The positive predictive value ranged between 4.3% and 21.0%, and the negative predictive value was between 98.0% and 99.8%. The rate of false-positives increased markedly at temperatures above 31.4 °C and relative humidities below 11.4%.

Although the POC test is a qualitative assay, the signal strength was scored on a scale from a weak 0.5 to a strong 5.0 in the field. There was a significant association between increased organism load and increased POC test signal strength. The Amplicor Chlamydia trachomatis PCR assay is a product of Roche Diagnostics (Burgess Hill, UK).

The authors concluded that the in its present format, this prototype POC test is not suitable for field diagnosis of ocular C. trachomatis as its specificity decreases in hot and dry conditions. In the absence of a suitable test for infection, trachoma diagnosis remains dependent on clinical signs and this will likely result in the unnecessary distribution of mass antibiotic treatment. The study was published on in the online journal Public Library of Science Neglected Tropical Diseases.

Related Links:
London School of Hygiene and Tropical Medicine
University of Cambridge
Roche diagnostics




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.